Revivogen - Study 6
back to Research
Studies on
active ingredients of Revivogen
Saw Palmetto
Testosterone metabolism in primary
cultures of human prostate epithelial cells and fibroblasts.
This Study shows that Fernistride and 4-MA
inhibited the formation of some testosterone Metabolites (including DHT), where
as Saw Palmetto inhibited the formation of all the Testosterone metabolites
studied.
Author: Délos S; Carsol JL; Ghazarossian E; Raynaud JP; Martin
PM
Journal: J Steroid Biochem Mol
Biol, 55: 3-4, 1995 Dec, 375-83
Abstract: We compare testosterone
(T) metabolism in primary cultures of epithelial cells and fibroblasts separated
from benign prostate hypertrophy (BPH) and prostate cancer tissues. In all
cultures, androstenedione (delta 4) formed by oxidation of T by 17 beta-hydroxysteroid
dehydrogenase (17 beta-HSD) represented 80% of the metabolites recovered. The
amounts of 5 alpha-dihydrotestosterone (DHT), formed by reduction of T by 5
alpha-reductase (5 alpha-R), were small: 5 and 2% (BPH) and 8 and 15% (adenocarcinoma)
for epithelial cells and fibroblasts, respectively. Northern blot analysis of
total RNA from epithelial cells (BPH or adenocarcinoma) attributed the reductive
activity to the 5 alpha-reductase type 1 isozyme and oxidative activity to the
17 beta-HSD type 2. In cancer fibroblasts, only little 17 beta-HSD type 2 mRNA
was detected. The 5 alpha-reductase inhibitors, 4-MA (17
beta-(N,N-diethyl)carbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one) and
finasteride, inhibited DHT formation with a preferential action of 4-MA on
epithelial cells (BPH or adenocarcinoma) and of finasteride on fibroblasts from
adenocarcinoma. Neither inhibitor acted on delta 4 formation. On the other hand,
the lipido-sterol extract of Serenoa repens (LSESr, Permixon, Saw Palmetto)
inhibited the formation of all the T metabolites studied [IC50 S = 40 and 200
micrograms/ml (BPH) and 90 and 70 micrograms/ml (adenocarcinoma) in epithelial
cells and fibroblasts, respectively]. These results have important therapeutic
implications when selecting appropriate treatment options for BPH.
|
